In conclusion, Gli inhibitors overcome Smo acquired resistance and inhibit Gli activatation via the Smo-independent noncanonical pathway, with robust anti-tumor activities in Gli-dependent tumors. The gene discussed is GLI1; the disease is neoplasm.